Olema Oncology breast cancer data a ‘home run,’ says H.C. Wainwright

H.C. Wainwright keeps a Buy rating on Olema Oncology with a $28 price target after the company presented updated monotherapy data on palazestrant from the Phase 2 study. The data is a “home run” and highlight that palazestrant could be a best-in-class therapy for second- and third-line ER+/HER2- metastatic breast cancer, the analyst tells investors in a research note. “Comparing palazestrant data to other oral SERDs in development, it is clear that palazestrant has potential to be best-in-class,” says H.C. Wainwright.